![Medidata says its planned $195 million acquisition of SHYFT Analytics is designed to foster development of a life sciences platform that combines clinical development with commercial and real-world data analytics. [Medidata]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1725-696x437.jpeg "Medidata says its planned $195 million acquisition of SHYFT Analytics is designed to foster development of a life sciences platform that combines clinical development with commercial and real-world data analytics. [Medidata]")
Medidata has agreed to acquire SHYFT Analytics for $195 million, in a deal designed to foster development of a life sciences platform that combines clinical development with commercial and real-world data analytics.
The companies’ combined Intelligent Platform for Life Sciences is designed to enhance drug and device discovery, development and commercialization by bringing together applications, services, and proven data science capabilities based on what Medidata and SHYFT call the largest global pool of research data, as well as customer relationship management (CRM) data, third-party commercial data, and real-world data sources.
